CTOs on the Move

AlloVir

www.allovir.com

 
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

AlloVir raised $120M on 05/23/2019

Similar Companies

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

VenatoRx

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company has also been awarded a contract from the NIH and funding from the Wellcome Trust to advance the company’s product candidates.

Interleukin Genetics

Interleukin Genetics Incorporated is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arzeda

Arzeda The Protein Design Company is a synthetic biology company.

Chromatin

Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and processors. At the same time, the company's technology can benefit the environment through decreased use of pesticides and fertilizers. The company's mini-chromosome technology simultaneously introduces multiple genetic traits into plants, reducing the time and cost required to develop improved and novel crop-based products, such as medicines, biomaterials, textiles and nutritionally improved foods. These products are enabled while allowing growers to enjoy the benefits of the most up-to-date agronomic traits, such as herbicide tolerance, pest resistance, and diseases resistance. Mini-chromosomes also provide unprecedented precision and control of new traits at every point in a plant's life cycle, from seed to field and beyond. Crop stewardship is at the core of Chromatin's values, and the company is equally focused on using its technology to introduce sustainable, healthy agricultural practices while enhancing commercial value and quality of life.